From GlobeNewswire:

Celldex Therapeutics, Inc. announced positive 12-week results from a Phase 2 clinical trial of barzolvolimab for chronic spontaneous urticaria (CSU) refractory to antihistamines. The humanized monoclonal antibody showed significant decreases in disease activity and a favorable safety profile. Data presented by Dr. Marcus Maurer at the AAAAI Annual Meeting highlighted rapid and sustained improvement in patients, including those previously treated with omalizumab. Results support barzolvolimab as a potential transformative treatment for CSU, with plans for a Phase 3 trial in 2024. Patients on various doses showed clinically meaningful responses, with potential for complete disease control.



Read more at GlobeNewswire: Celldex Therapeutics Presents Positive 12 Week Results from